SWOG Plenary I Translational Medicine Science as the Foundation for Rapid and Meaningful Advances in Oncology

Lee M. Ellis, MD SWOG Vice Chair, Translational Medicine Departments of Surgical Oncology and Molecular & Cellular Oncology UT MD Anderson Cancer Center

Thanks to James Rae, PhD (AKA J.R.) SWOG Executive Officer, Translational Medicine

Presenter Disclosure Information

Lee Ellis, MD, FASCO: Data Monitoring Committee for Roche

Luiz Diaz, Jr., MD: Consultant for Merck and PGDx. Stock Shareholder in PGDx, Papgene, and Jounce Therapeutics.

Nikolaus Schultz, PhD: No Disclosures

Timothy Yap, MD, PhD: Consultant for Merck, AstraZeneca, Clovis, Pfizer, EMD Serono, Atrin, Aduro, Roche, and Janssen. Speaker's Bureau for Tesaro, AstraZeneca, and Merck. Research grant from Pfizer, Tesaro, and Merck.



Leading cancer research. Together.

Quick Overview of Translational Medicine at SWOG

 The vast majority of work is done within each committee: thanks to all for your commitment and expertise

Thanks to NCI, The Hope Foundation, and ITSC Partners for support on innumerable initiatives!

- Overview of upcoming funding opportunities
- Next SWOG meeting
- EORTC Fellowship Opportunity

 EORTC leadership are here at SWOG to discuss collaborative opportunities and answer question regarding the fellowship

"Liquid Biopsies – Using Cell-Free DNA Methodologies to Assess Clinical Trial Outcomes" Thursday October 4, 2018 | 6:00pm – 9:00pm

6:00pm - 6:05pm "Welcome and Introductions"

James M Rae, PhD Rogel Cancer Center, University of Michigan

Session 1 6:05pm-7:05pm.

"How to Choose the Right Platform for Your Clinical Trial"

Chair: Honey V Reddi, PhD, FACMG Clinical Laboratory Director, The Jackson Laboratory for Genomic Medicine

1) Honey V Reddi, PhD, FACMG

Clinical Laboratory Director, The Jackson Laboratory for Genomic Medicine *"Technical Considerations for Taking Liquid Biopsy to the Clinic"*

2) Philip C. Mack, PhD

UC Davis Comprehensive Cancer Center "Clinical Utility of ctDNA Analysis"

3) Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics, MDACC

"Opportunities and Challenges of Incorporating cfDNA into Clinical Trials" Session 2 7:05pm – 8:05pm.

Novel trail designs with ctDNA

Chair: Dan Levy, PhD Cold Spring Harbor Laboratory

1) Alex Herrera, MD

Beckman Research Institute at the City of Hope "Incorporating ctDNA into Lymphoma Clinical Trials"

2) Van K. Morris, MD

Department of Gastrointestinal Medical Oncology, MDACC "ctDNA as a Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colon Cancer"

3) Filip Janku, MD, PhD

Department of Investigational Cancer Therapeutics, MDACC

"Liquid Biopsies in Personalized Medicine Strategies in Early Phase Clinical Trials"

8:00-8:15pm Break (beer, wine, snacks) Session 3 8:15pm – 9:00pm.

"Commercial ctDNA Platforms"

Chair: Lee Ellis, MD SWOG Vice Chair for TM

1) Guardant Health, Inc. Becky Nagy, MS LGC Director, Medical Affairs

2) PGDx, Personal Genome Diagnostics, Inc.

Luis A. Diaz, MD "New insights in clinical application of ctDNA"

3) Foundation Medicine, Inc. Jon Chung, PhD

Associate Director, Clinical Development "Hybrid Capture-based Genomic Profiling of ctDNA to Assess Genomic Alterations and Tumor Mutational Burden"

4) DiaCarta, Inc. Paul Okunieff, MD

"Using XNA Clamps as Liquid Biopsies for Screening, Follow up Evaluation, and for Personalized Quantitative Measurement of Drug Response"

2018 ITSC Workshop



June 27-29, 2018

The Jackson Laboratory Bar Harbor, Maine

Funding: The Hope Foundation; U10CA180944; JAX; CSHL

THE HOPE FOUNDATION

Because answers to cancers come from clinical trials

SWOG Early Exploration and Development (SEED) Fund	Up to \$50,000 – Funding preliminary research that will translate to clinical trials or trial-associated projects; 1 or 2- year projects	Next deadline December 1, 2018
SWOG Impact Award Program	Up to \$250,000 – Mechanism for translating scientific discovery to patient care; intended to encourage innovative approaches; 1 or 2-year projects	Next deadline March 1, 2019

All funding opportunities: thehopefoundation.org/research-funding

25 Years of Supporting SWOG



THE HOPE FOUNDATION

\$988K provided for Integrated Translational Science Center (**ITSC**) pilot grants since 2014

25 Impact Awards granted since 2011

18 Coltman Fellows funded since 2008

100 Young Investigators supported since 1999

90% of every contribution directly invested in SWOG Please give today! Text "SWOG" to 41444

2019 Spring SWOG Meeting

- Plenary 1, SWOG San Francisco
 - Ignacio Wistuba, MD, CIMAC
 - Edison Liu, MD, ITSC/SWOG Collaborations
 - TBD
- TM Chair dinner to discuss new ideas, collaborations, educational needs and programs

Thursday Evening

EORTC Leadership at SWOG



Dr. Denis Lacombe is involved in the coordination and administration of all EORTC activities to promote EORTC as a major European organisation in cancer clinical and translational research. He is responsible for scientific and public policy activities, developing and implementing medium-term strategies as defined by the EORTC Board, and internal and external communications.



Dr. Vassilis Golfinopoulos oversees the Medical department, including the Translational Research and Pharmacovigilance, Clinical Operations, and the QOLdepartments at EORTC. His tasks include developing and implementing scientific strategy and supporting EORTC Board initiatives. He also acts as clinical research physician for the EORTC Brain Tumour group.



BAEF-EORTC Fellowship

- Work and learn on all aspects of clinical research in Europe
- Develop and understand modalities for international cooperation (30 countries)
- Contribute to EORTC clinical research activities in a multicultural and multinational environment
- Evolve in a highly professional clinical research coordinating facility in partnership with European scientific leaders
- Open to US citizens: MD, statisticians, data science specialists
- More detailed information on EORTC website <u>http://www.eortc.org/education-training/fellowship/eortc-baef-fellowship</u>
- 160 visiting fellows have joined EORTC in the last 25 years

Flyers describing the fellowship are on the registration desk.

Plenary 1: Translational Medicine

3:10 - 3:35 pm Targeting the DNA Damage Response: Lessons Learned and the Path Forward Timothy A. Yap, MD, PhD MD Anderson Cancer Center

3:35 - 4:00 pm Opportunities and Limitations of ctDNA as a Clinical Biomarker in Cancer Management Luis A. Diaz, MD Memorial Sloan Kettering Cancer Center

4:00 - 4:25 pm

Identifying Driver Alterations and Therapeutic Options in Tumor Samples using the cBioPortal and OncoKB Nikolaus Schultz, PhD Memorial Sloan Kettering Cancer Center

Flims Course, 2015

